Your session is about to expire
← Back to Search
Cabozantinib + Nivolumab for Advanced Prostate Cancer (CANOPY Trial)
CANOPY Trial Summary
This trial tests a drug combo to treat advanced prostate cancer.
CANOPY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCANOPY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CANOPY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a condition that prevents my body from absorbing nutrients properly.My prostate cancer has been confirmed by lab tests.My brain metastases have been treated and stable for at least 4 weeks.I am a man aged 18 or older.I have or am at immediate risk of having spinal cord compression.I have had more than one chemotherapy treatment, not counting first-generation anti-androgens.I do not have active hepatitis B/C or TB requiring treatment.My cancer is of small cell or neuroendocrine type.I have a history of lung scarring or inflammation not caused by infections.I have not had radiation therapy in the week before starting the study treatment.I have had a solid organ or bone marrow transplant.I haven't taken any cancer treatment drugs in the last 4 weeks.I have not received a live vaccine in the last 30 days.I do not have any major health issues that are not under control.I can take care of myself and am up and about more than 50% of my waking hours.I require dialysis.I do not take more than 10 mg of prednisone daily for an autoimmune disease.I have been treated with a taxane and a hormone therapy for my cancer, or I cannot or will not take taxane.I am HIV-positive, on stable treatment, with undetectable viral load and CD4 count over 350.I haven't taken any kinase inhibitor medication in the last 2 weeks.I have previously been treated with cabozantinib or checkpoint inhibitors.My recent tests show my organs are functioning well.I cannot swallow pills.My side effects from previous treatments are mild or back to normal.My prostate cancer is worsening despite low testosterone levels.I am currently taking certain blood thinners not allowed in the study.I haven't taken abiraterone, apalutamide, darolutamide, or enzalutamide in the last 2-4 weeks.
- Group 1: Experimental Group
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards may be associated with participation in the Experimental Group?
"Our team at Power assigns a score of 2 to Experimental Group, due to its Phase 2 status. This signifies that clinical data exists regarding the treatment's safety but none yet related to efficacy."
How many participants are currently contributing to this medical experiment?
"Affirmative. According to the information published on clinicaltrials.gov, this medical research is actively recruiting participants since it was posted on February 2nd 2023 and recently updated with the same date. 50 volunteers need to be recruited from a single centre."
Is there currently an opportunity for individuals to partake in this medical investigation?
"Affirmative. Clinicaltrials.gov provides evidence of this medical trial's active recruitment, beginning on February 2nd 2023 and updated at the same time. The research is enrolling 50 participants from a single site."
Share this study with friends
Copy Link
Messenger